X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Middle East and South Asia

Prolor Biotech R&D Facility, Weizmann Science Park, Israel

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Middle East and South Asia, Projects

Prolor Biotech, a clinical phase biopharmaceutical company formerly known as Modigene, has opened a new corporate headquarters and R&D facility within the Weizmann Science Park, a major biotech cluster located in Ness Ziona, Israel.

The facility is located close to the company’s existing facility within the park. Prolor is expected to relocate operations to the new facility by the end of the first half of 2011.

The new facility will propel the Prolor’s growth across all fields, including new drug research and clinical development. It will allow the company to develop a host of therapeutic proteins at substantially reduced costs and with quicker production cycles and superior control.

The relocation is subject to positive results from the company’s Phase II clinical trial on its longer acting version of human growth hormone. Positive preliminary results from the randomised, open-label and multicentre trial were announced on 11 April 2011; final results are expected to be released by the second half of 2011.

Facility

 

The new facility occupies 10,000ft² of rented space within the park. Its R&D area houses several cleanroom suites designed for the development of therapeutic drug candidates to GMP standards.

The company’s existing facility occupies 6,000ft² and has dedicated molecular biology laboratories, cell culture laboratories, in-vitro potency and activity testing laboratories, protein purification laboratories, pharmaceutical development laboratories and analytical development laboratories. The lease of the existing facility is due to expire on 20 January 2012.

“The relocation is subject to positive results from Prolor’s Phase II clinical trial on its longer acting version of human growth hormone.”

Production

 

The new facility will produce therapeutic drug candidates. Prolor Biotech’s current pipeline of therapeutic proteins and peptides include human growth hormone, interferon ß, factor VIIa, erythropoietin, GLP-1 and OXY-CTP – all of which are in the developmental stage and targeted for markets valued between $1bn and $10bn.

The facility will additionally be dedicated to Phase I clinical studies for new indications of its drug candidates, including both approved drugs and drugs in the clinical stage of development. This will include a drugs for haemophilia and obesity. Phase II and III clinical trials will be outsourced to third-party pharmaceutical companies.

Technology

 

The facility will be equipped with Prolor Biotech’s proprietary carboxyl terminal peptide (CTP) technology to develop longer-acting, patented versions of therapeutic proteins. CTP is an amino acid sequence released naturally within the body, which is bound to a therapeutic protein.

The technology is compatible with all proteins and has proved to be non-immunogenic to humans when bound to proteins. It prolongs the duration of protein activity within the body. The technology stabilises therapeutic protein molecules in the blood and reduces its elimination from the body without increasing the level of toxicity or changing the overall biological activity.

Therapeutic proteins industry

 

“The facility will be equipped with Prolor Biotech’s proprietary carboxyl terminal peptide technology .”

The global therapeutic proteins market is one of the fastest growing segments of the biopharmaceutical industry. Worldwide sales of therapeutic proteins are projected to reach $77bn by 2011, according to industry analysts RNCOS. The sector reported a 14% growth in 2008.

Competition is expected to increase over the next ten years as several proteins in the market are expected to go off patent. In addition, improved versions and other therapeutic proteins will pose increased competition to several commercial proteins. Aside from erythropoietin, none of the therapeutic proteins Prolor Biotech has in development has any substitute in the market.

Tags: Middle East & South Asia
Previous Post

DuBiotech, United Arab Emirates

Next Post

Cleanroom Technology Market Growth to 2019 Driven by APAC and Latin America

Related Posts

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Next Post

Cleanroom Technology Market Growth to 2019 Driven by APAC and Latin America

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In